was founded in August 2001 by Professor Dr. Konrad Burk who is responsible
for scientific and medical matters. In addition to his excellent professional
qualifications, Dr. Burk has 30 years of practical experience in both clinical
and industry settings, with a focus on oncology and urology.
Dr. Burk has established excellent connections with organizations and
institutions that are well known in the oncology field. These relationships
include such names as the Cancer Research Campaign (CRC), the German Cancer
Society (DKG), the European Organization for Research and Treatment of
Cancer (EORTC), the National Surgical Adjuvant Breast and Bowel Project
(NSABP), the MD Anderson Cancer Center, Houston, Texas and the Memorial
Sloan Kettering Cancer Center, New York, NY.
During his employment with academic hospitals as well as in clinical research
and development Dr. Burk has conducted numerous clinical trials in cooperation
with the aforementioned institutions. The contacts and personal relationships
resulting from this, enable ClinDescience
to cooperate very closely with experienced experts in toxicology, pharmacology,
clinical, and regulatory in Europe and the United States.
The customized strategies and concepts developed by ClinDescience
will support your decision-making in complex situations of drug development.
Our goal is to contribute to a substantial reduction in the development
time of your compounds.
Our expertise will
help you in evaluating the potential of a compound.
The first step is a thorough risk-benefit analysis of the compound under
consideration. It is important to harmonize the pre-clinical investigations
and the clinical development program. In addition, the approval strategy
will have a significant impact on the clinical study program.
We will draft an individual development plan for your compounds based on our scientific
expertise and our many years of experience in this industry. Of specific
note is our experience in dealing with the regulatory authorities governing
clinical and drug development. In this area of the business, we are able
to clearly determine the likelihood of success and the risks associated
with different options.
The core focus of ClinDescience
is to join with pharmaceutical and biotech companies in drug development
from the pre-clinical phase through to the approval process. This can
take place in close cooperation with the advisory boards and the regulatory
authorities in Europe and the USA. Such cooperation will support your
current drug development programs and will result in a reduced overall
We combine a deep know-how in basic research with international experience in clinical
issues and drug approval. Our relationships with internationally acclaimed
experts enable us to call on their expertise when there is a need to provide